09
Apr

Mille studi sugli effetti collaterali dei vaccini Covid. Dove scaricare il documento integrale

Raccolti in un solo documento 1000 studi sottoposti a revisione paritaria che mettono in dubbio la sicurezza del vaccino Covid-19
Si tratta di documenti medici sottoposti a revisione paritaria inviati a varie riviste mediche, che evidenziano una moltitudine di eventi avversi nei destinatari del vaccino Covid-19.

Si può scaricare il documento integrale qui (lo trovate in fondo alla pagina): https://web.archive.org/web/20220225041134/https://www.informedchoiceaustralia.com/post/1000-peer-reviewed-studies-questioning-covid-19-vaccine-safety

Link per scaricare il PDF sparito dalla pagina archiviata:
Per rintracciare il PDF online, bisogna cercare qualcosa di simile alla seguente stringa:
Updated_Peer_Reviewed_medical_papers_submitted_to_various_medical.pdf
Si parte dalla miocardite, per arrivare a sindromi più rare, ma ugualmente pericolose.

Peer Reviewed Medical Papers Submitted To Various Medical Journals, Evidencing A Multitude Of Adverse Events In Covid-19 Vaccine Recipients
  1. Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: https://sciencedirect.com/science/article/pii/S2666602221000409
  2. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis wasidentified within 4 days after receipt of the vaccine”: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
  3. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
  4. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19vaccination: https://pediatrics.aappublications.org/content/early/ 2021/06/04/peds.2021-052478
  5. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for careproviders: https://sciencedirect.com/science/article/pii/ S0828282X21006243
  6. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: https://sciencedirect.com/science/article/pii/S1443950621011562
  7. Myocarditis with COVID-19 mRNA vaccines: https://ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135
  8. Myocarditis and pericarditis after COVID-19 vaccination: https://jamanetwork.com/journals/jama/fullarticle/2782900
  9. Myocarditis temporally associated with COVID-19 vaccination: https://ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891.
  10. COVID-19 Vaccination Associated with Myocarditis in Adolescents: https://aappublications.org/content/pediatrics/early/2021/08/12/peds. 2021-053427.full.pdf
  11. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https://pubmed.ncbi.nlm.nih.gov/33994339/
  12. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report andreview of the literature: https://sciencedirect.com/ science/article/pii/S1553838921005789
  13. COVID-19 vaccine-induced myocarditis: a case report with review of the literature: https://sciencedirect.com/science/article/pii/S1871402121002253


  1. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: https://sciencedirect.com/science/article/pii/S1936878X2100485X
  2. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https://sciencedirect.com/science/article/pii/S002234762100617X
  3. Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https:// sciencedirect.com/science/article/pii/S0167527321012286.
  4. Acute myocarditis after administration of BNT162b2 vaccine: https://sciencedirect.com/science/article/pii/S2214250921001530
  5. Lymphohistocytic myocarditis after vaccination with COVID-19 COV2.S viral vector: https://www.sciencedirect.com/science/article/pii/S2352906721001573
  6. Myocarditis following vaccination with BNT162b2 in a healthy male: https://sciencedirect.com/science/article/pii/S0735675721005362
  7. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2infection: https://sciencedirect.com/science/article/pii/ S1930043321005549
  8. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: https://sciencedirect.com/science/article/pii/S2589790X21001931
  9. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: https://sciencedirect.com/science/article/pii/S0870255121003243
  10. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https://sciencedirect.com/science/article/pii/ S1936878X21004861
  11. COVID-19 mRNA vaccination and myocarditis: https://pubmed.ncbi.nlm.nih.gov/ 34268277/
  12. COVID-19 vaccine and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34399967/
  13. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNAvaccine in Korean children: a multicenter study https:// bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc e/en/ covidwho-1360706.
  14. COVID-19 vaccines and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34246566/
  15. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccineshttps://cureus.com/articles/61030-myocarditis-and-other- cardiovascular-complications-of-the-mrna-based-covid-19-vaccines
  16. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccineshttps://cureus.com/articles/61030-myocarditis-and-other- cardiovascular-complications-of-the-mrna-based-covid-19-vaccines
  17. Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34340927/
  18. Myocarditis with covid-19 mRNA vaccines: https://ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135


  1. Association of myocarditis with COVID-19 mRNA vaccine in children: https://jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co vid-19- vaccine-in-children/
  2. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series ofchildren: https://jamanetwork.com/journals/jamacardiology/fullarticle/ 2783052
  3. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the

U.S. military: https://jamanetwork.com/journals/jamacardiology/fullarticle/ 2781601%5C

  1. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600
  2. Myocarditis following immunization with Covid-19 mRNA: https://nejm.org/doi/full/10.1056/NEJMc2109975
  3. Patients with acute myocarditis after vaccination withCOVID-19 mRNA: https://com/journals/jamacardiology/fullarticle/2781602
  4. Myocarditis associated with vaccination with COVID-19 mRNA: https://pubs.rsna.org/doi/10.1148/radiol.2021211430
  5. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: https://pediatrics.aappublications.org/content/148/3/e2021052478
  6. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://jcmr-biomedcentral.com/articles/10.1186/s12968-021-00795-4
  7. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: https://cps.ca/en/documents/position/ clinical-guidance-for-youth-with-myocarditis-and-pericarditis
  8. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https://ncbi.nlm.nih.gov/34402228/
  9. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
  10. Myocarditis / pericarditis associated with COVID-19 vaccine: https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html
  11. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/
  12. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magneticresonance imaging findings: https://ahajournals.org/ doi/10.1161/CIRCIMAGING.121.013236
  13. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: https://ahajournals.org/doi/10.1161/ CIRCULATIONAHA.121.056038
  14. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence orrather a vaccination-associated autoimmune myocarditis?: https://pubmed.ncbi.nlm.nih.gov/34333695/


  1. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https:// ncbi.nlm.nih.gov/pmc/articles/PMC8216855/
  2. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: https://ncbi.nlm.nih.gov/34118375/
  3. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: https:// ncbi.nlm.nih.gov/34180390/
  4. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
  5. Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
  6. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34514306/
  7. Acute myocardial infarction within 24 hours after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34364657/.
  8. fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https:// ncbi.nlm.nih.gov/34416319/.
  9. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34514078/
  10. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratifiedanalysis of a national database: https://medrxiv.org/content/ 10.1101/2021.08.30.21262866v1
  11. A report of myocarditis adverse events in the S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: https:// pubmed.ncbi.nlm.nih.gov/34601006/
  12. This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: https://nejm.org/doi/full/10.1056/NEJMoa2110475
  13. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratifiedanalysis of a national database: https://medrxiv.org/content/ 10.1101/2021.08.30.21262866v1.
  14. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co- vaccination:https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ ciab989/644 5179.
  15. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination ofincidence rate: https://academic.oup.com/cid/advance-article/doi/ 1093/cid/ciab926/6420408
  16. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://mdpi.com/2075-4426/11/11/1106
  17. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNAvaccine in Korean children: a multicenter study: https:// ncbi.nlm.nih.gov/34402230/


  1. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
  2. Myocarditis Following mRNA COVID-19 Vaccine: https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.
  3. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: https://ncbi.nlm.nih.gov/34614328/.
  4. Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: https://heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext
  5. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
  6. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: https://pubmed.ncbi.nlm.nih.gov/34246586/
  7. Hypersensitivity Myocarditis and COVID-19 Vaccines: https://ncbi.nlm.nih.gov/34856634/.
  8. Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: https://internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext.
  9. Acute myocardial infarction and myocarditis after COVID-19 vaccination: https://ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/
  10. Myocarditis after Covid-19 vaccination in a large healthcare organization: https://nejm.org/doi/10.1056/NEJMoa2110737
  11. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series ofchildren: https://jamanetwork.com/journals/jamacardiology/fullarticle/ 2783052
  12. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https://ahajournals.org/doi/abs/10.1161/ CIRCULATIONAHA.121.056583?

url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  1. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. https://pubmed.ncbi.nlm.nih.gov/34756746/
  2. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: https://ncbi.nlm.nih.gov/labs/pmc/ articles/PMC8587334/
  3. Myocarditis after COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/ 34546329/.
  4. Patients with acute myocarditis after COVID-19 mRNA vaccination:. https://com/journals/jamacardiology/fullarticle/2781602.
  5. Myocarditis after COVID-19 vaccination: a case series: https://sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub.
  6. Myocarditis associated with COVID-19 vaccination in adolescents: https://aap.org/pediatrics/article/148/5/e2021053427/181357
  7. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34704459/
  8. Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: https://oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6 421640.


  1. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: https://ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/
  2. Myocarditis after COVID-19 vaccination: https://sciencedirect.com/science/article/pii/S2352906721001603
  3. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic leftventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/ 34712717/.
  4. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https://revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration- bnt162b2-S188558572100133X.
  5. Myocarditis associated with COVID-19 mRNA vaccination: https://pubs.rsna.org/doi/1148/radiol.2021211430
  6. Acute myocarditis after COVID-19 vaccination: a case report: https://sciencedirect.com/science/article/pii/S0248866321007098
  7. Acute myopericarditis after COVID-19 vaccination in adolescents:. https://ncbi.nlm.nih.gov/34589238/.
  8. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: https://oup.com/jpids/article/10/10/962/6329543.
  9. Acute myocarditis associated with anti-COVID-19 vaccination: https://ecevr.org/ php?id=10.7774/cevr.2021.10.2.196.
  10. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. https://pubmed.ncbi.nlm.nih.gov/34428917/.
  11. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. https://pubmed.ncbi.nlm.nih.gov/34088762/.
  12. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ ehjqcco/qcab090/64 42104.
  13. COVID 19 vaccine for Concern for myocarditis and pericarditis: https:// www.mdpi.com/2036-7503/13/3/61.
  14. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https://ncbi.nlm.nih.gov/34402228/
  15. Myocarditis temporally associated with COVID-19 vaccination: https://ncbi.nlm.nih.gov/34133885/
  16. Acute myocarditis associated with COVID-19 vaccination: report of a case: https://ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/
  17. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: https://pubmed.ncbi.nlm.nih.gov/34840235/.
  18. Myocarditis in the setting of a recent COVID-19 vaccination: https://ncbi.nlm.nih.gov/34712497/.
  19. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: https://clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.
  20. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D- dimer in Thais after vaccination with ChAdOx1 nCoV-19: https:// ncbi.nlm.nih.gov/34568726/


  1. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co- vaccination:https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ ciab989/6445179
  2. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence ratedetermination: https://academic.oup.com/cid/advance-article/doi/ 1093/cid/ciab926/6420408.
  3. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://mdpi.com/2075-4426/11/11/1106
  4. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNAvaccine in Korean children: a multicenter study: https:// ncbi.nlm.nih.gov/34402230/
  5. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
  6. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co- vaccination: https://pubmed.ncbi.nlm.nih.gov/34849657/.
  7. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: https:// ncbi.nlm.nih.gov/34664804/
  8. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: https://pubmed.ncbi.nlm.nih.gov/34605853/
  9. Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNAdisease vaccine (COVID-19) in an adolescent male: https:// ncbi.nlm.nih.gov/34166671/
  10. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNAvaccination: https://pubmed.ncbi.nlm.nih.gov/34744118/
  11. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: https://ncbi.nlm.nih.gov/34334935/.
  12. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34746968/
  13. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidenceor rather a vaccination-associated autoimmune myocarditis?”: https://pubmed.ncbi.nlm.nih.gov/34333695/.
  14. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: https:// ncbi.nlm.nih.gov/34180390/
  15. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: https://pubmed.ncbi.nlm.nih.gov/34185045/
  16. Myocarditis after BNT162b2 vaccination in a healthy male: https://ncbi.nlm.nih.gov/34229940/
  17. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: https://ncbi.nlm.nih.gov/34308326/.
  18. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/


  1. Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273:https://pubmed.ncbi.nlm.nih.gov/34848416/
  2. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34367386/
  3. Acute myocarditis in a young adult two days after vaccination with Pfizer: https://ncbi.nlm.nih.gov/34709227/
  4. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: https://pubmed.ncbi.nlm.nih.gov/34778411/
  5. Acute myocarditis after 2019 coronavirus disease vaccination: https://ncbi.nlm.nih.gov/34734821/
  6. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34246585/
  7. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: https://pubmed.ncbi.nlm.nih.gov/34866122/
  8. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: https://pubmed.ncbi.nlm.nih.gov/34601566/
  9. Myocarditis following COVID-19 vaccination: MRI study: https://ncbi.nlm.nih.gov/34739045/.
  10. Acute myocarditis after COVID-19 vaccination: case report: https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e
  11. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a caseseries of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
  12. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https://pubmed.ncbi.nlm.nih.gov/34865500/
  13. Myocarditis following vaccination with Covid-19 in a large healthcare organization: https://pubmed.ncbi.nlm.nih.gov/34614329/
  14. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34849667/
  15. Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: https://ncbi.nlm.nih.gov/34396358/.
  16. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccineproduct, schedule, and interval: https://medrxiv.org/content/ 10.1101/2021.12.02.21267156v1
  17. Acute myocardial infarction and myocarditis after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34586408/
  18. Abbate, , Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides,
  19. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. https:// www.ncbi.nlm.nih.gov/pubmed/34416319
  20. Abu Mouch, S., Roguin, , Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021).Myocarditis following COVID-19 mRNA vaccination. Vaccine,


39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. https://www.ncbi.nlm.nih.gov/ pubmed/34092429

  1. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/ j.radcr.2021.05.033. https://www.ncbi.nlm.nih.gov/pubmed/34025885
  2. Aye, N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S.

(2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. https://www.ncbi.nlm.nih.gov/pubmed/34586408

  1. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in anAdolescent Patient After mRNA COVID-19 J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. https:// www.ncbi.nlm.nih.gov/pubmed/34756746
  2. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation,144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135.

https://www.ncbi.nlm.nih.gov/pubmed/34281357

  1. Calcaterra, , Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/ pediatric13030061. https://www.ncbi.nlm.nih.gov/pubmed/34564344
  2. Chamling, , Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz,
  3. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol,110(11), 1850-1854. doi:10.1007/ s00392-021-01916-w. https://www.ncbi.nlm.nih.gov/pubmed/34333695
  4. Chelala, , Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. https:// www.ncbi.nlm.nih.gov/pubmed/34704459
  5. Choi, , Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S.

(2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: CaseReport Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. https:// www.ncbi.nlm.nih.gov/pubmed/34664804

  1. Chua, T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . .

Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents FollowingComirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ ciab989. https://www.ncbi.nlm.nih.gov/pubmed/34849657

  1. Clarke, , & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. https://www.ncbi.nlm.nih.gov/pubmed/ 34933012
  2. Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7).doi:10.3390/children8070607. https://www.ncbi.nlm.nih.gov/ pubmed/34356586


  1. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, P.(2021). A Series of Patients With Myocarditis Following SARS- CoV-2 Vaccination With mRNA-1279 andBNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003.https://www.ncbi.nlm.nih.gov/ pubmed/34246585
  2. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, (2021).Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6.https://www.ncbi.nlm.nih.gov/pubmed/

34487236

  1. Facetti, S., Giraldi, M., Vecchi, L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a youngadult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. https://www.ncbi.nlm.nih.gov/pubmed/

34709227

  1. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 EurHeart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. https://www.ncbi.nlm.nih.gov/pubmed/34849667
  2. Gargano, W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from theAdvisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27),

977-982. doi:10.15585/mmwr.mm7027e2. https://www.ncbi.nlm.nih.gov/pubmed/

34237049

  1. Gautam, , Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation ofCOVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. https://www.ncbi.nlm.nih.gov/pubmed/34660088
  2. Gellad, F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. https://www.ncbi.nlm.nih.gov/pubmed/34916217
  3. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/ 3454412
  4. Ioannou, (2021a). Myocarditis should be considered in those with a troponin rise and unobstructedcoronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. https://www.ncbi.nlm.nih.gov/pubmed/34463755
  5. Ioannou, (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm anacute inflammatory process. QJM. doi:10.1093/qjmed/ hcab326. https://www.ncbi.nlm.nih.gov/pubmed/34931681
  6. Isaak, , Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology,301(1), E378-E379. doi:10.1148/radiol.2021211766. https:// www.ncbi.nlm.nih.gov/pubmed/34342500
  7. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, , . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional


pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/ gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376

  1. Jain, S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. https:// www.ncbi.nlm.nih.gov/pubmed/34389692
  2. Kaneta, , Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. https://www.ncbi.nlm.nih.gov/ pubmed/34744118
  3. Kaul, , Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza,
  4. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872.doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/

34568540

  1. Kim, W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA

COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio. 2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046

  1. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229.https://www.ncbi.nlm.nih.gov/pubmed/ 34402228
  2. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS- CoV-2, a case Am Heart J Plus, 8, 100042.doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358
  3. Kwan, Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . .

. Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. https://www.ncbi.nlm.nih.gov/ pubmed/34393110

  1. Lee, , Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi: 10.1093/qjmed/hcab232. https://www.ncbi.nlm.nih.gov/pubmed/34463770
  2. Levin, , Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. https:// www.ncbi.nlm.nih.gov/pubmed/34535317
  3. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine J Pers Med, 11(11). doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/ 34834458
  4. Lim, , Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E.

(2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA CoronavirusDisease 2019 Vaccination Requiring Extracorporeal


Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/ fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411

  1. Luk, , Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001.https://www.ncbi.nlm.nih.gov/pubmed/

34375696

  1. Mevorach, , Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy- Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. https:// www.ncbi.nlm.nih.gov/pubmed/34614328
  2. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis TemporallyAssociated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male J Pediatr, 238, 321-323. doi: 10.1016/j.jpeds.2021.06.035. https://www.ncbi.nlm.nih.gov/pubmed/34166671
  3. Montgomery, , Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr.(2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi: 10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045
  4. Murakami, , Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). MyocarditisFollowing a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21. https:// www.ncbi.nlm.nih.gov/pubmed/34840235
  5. Nagasaka, , Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021).Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006. https:// www.ncbi.nlm.nih.gov/pubmed/34876937
  6. Park, , Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J.

(2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNACOVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232. doi:10.3346/jkms.2021.36.e232. https:// www.ncbi.nlm.nih.gov/pubmed/34402230

  1. Park, , Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young, 1-4. doi:10.1017/S1047951121002547. https://www.ncbi.nlm.nih.gov/pubmed/34180390
  2. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19vaccination: a case J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-4. https:// www.ncbi.nlm.nih.gov/pubmed/34496880
  3. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19vaccination or SARS-CoV-2 Nat Med. doi:10.1038/s41591-021-01630-0. https://www.ncbi.nlm.nih.gov/pubmed/ 34907393


  1. Patrignani, , Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021).Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection.Radiol Case Rep, 16(11), 3321-3325. doi: 10.1016/j.radcr.2021.07.082. https://www.ncbi.nlm.nih.gov/pubmed/34367386
  2. Perez, , Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021).Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. doi:10.1093/cid/ciab926. https:// www.ncbi.nlm.nih.gov/pubmed/34734240
  3. Shiyovich, , Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan,
  4. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jeab230. https:// www.ncbi.nlm.nih.gov/pubmed/34739045
  5. Simone, , Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute MyocarditisFollowing COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670. doi:10.1001/jamainternmed. 2021.5511. https://www.ncbi.nlm.nih.gov/pubmed/34605853
  6. Singer, E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from

COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101/2021.07.23.21260998. https://www.ncbi.nlm.nih.gov/pubmed/34341797

  1. Starekova, J., Bluemke, D. , Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021).Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-E411. doi:10.1148/radiol.2021211430. https:// www.ncbi.nlm.nih.gov/pubmed/34282971
  2. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19COV2.S vaccine and acute myocarditis: A case report and literature review. Cardiovasc Revasc Med. doi:10.1016/j.carrev.2021.08.012. https://www.ncbi.nlm.nih.gov/pubmed/34420869
  3. Tailor, D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093/ehjcr/ytab319. https:// www.ncbi.nlm.nih.gov/pubmed/34514306
  4. Takeda, , Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J. doi:10.1253/circj.CJ-21-0935. https://www.ncbi.nlm.nih.gov/ pubmed/34955479
  5. Truong, T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescentsand Young Adults. Circulation. doi: 10.1161/CIRCULATIONAHA.121.056583. https://www.ncbi.nlm.nih.gov/pubmed/ 34865500
  6. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, , Ferrari, V. A., & Han, Y. (2021).Myocarditis and Other Cardiovascular Complications of the mRNA- Based COVID-19 Vaccines. Cureus, 13(6), e15576. doi:10.7759/cureus.15576. https://www.ncbi.nlm.nih.gov/pubmed/34277198


  1. Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584. doi: 1097/PEC.0000000000002557. https://www.ncbi.nlm.nih.gov/pubmed/34731877
  2. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in ahealthy Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051. https://www.ncbi.nlm.nih.gov/pubmed/34229940
  3. Witberg, , Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski,
  4. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med,385(23), 2132-2139. doi:10.1056/NEJMoa2110737. https://www.ncbi.nlm.nih.gov/pubmed/34614329
  5. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/ 3454412
  6. Ioannou, (2021a). Myocarditis should be considered in those with a troponin rise and unobstructedcoronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. https://www.ncbi.nlm.nih.gov/pubmed/34463755
  7. Isaak, , Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology,301(1), E378-E379. doi:10.1148/radiol.2021211766. https:// www.ncbi.nlm.nih.gov/pubmed/34342500
  8. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/ gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376
  9. Jain, S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. https:// www.ncbi.nlm.nih.gov/pubmed/34389692
  10. Kaneta, , Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. https://www.ncbi.nlm.nih.gov/ pubmed/34744118
  11. Kaul, , Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza,
  12. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872.doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/

34568540

  1. Kim, W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA

COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.

2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046

  1. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229.https://www.ncbi.nlm.nih.gov/pubmed/ 34402228


  1. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS- CoV-2, a case Am Heart J Plus, 8, 100042.doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358
  2. Kwan, Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K.

Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. https:// www.ncbi.nlm.nih.gov/pubmed/34393110

  1. Lee, , Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi: 10.1093/qjmed/hcab232. https://www.ncbi.nlm.nih.gov/pubmed/34463770
  2. Levin, , Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. https:// www.ncbi.nlm.nih.gov/pubmed/34535317
  3. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine J Pers Med, 11(11). doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/ 34834458
  4. Lim, , Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E.

(2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA CoronavirusDisease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/ fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411

  1. Luk, , Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001.https://www.ncbi.nlm.nih.gov/pubmed/

34375696

  1. Mevorach, , Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy- Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. https:// www.ncbi.nlm.nih.gov/pubmed/34614328
  2. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis TemporallyAssociated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male J Pediatr, 238, 321-323. doi: 10.1016/j.jpeds.2021.06.035. https://www.ncbi.nlm.nih.gov/pubmed/34166671
  3. Montgomery, , Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr.(2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi: 10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045
  4. Murakami, , Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). MyocarditisFollowing a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21. https:// www.ncbi.nlm.nih.gov/pubmed/34840235


  1. Nagasaka, , Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021).Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006. https:// www.ncbi.nlm.nih.gov/pubmed/34876937
  2. Premature myocardial infarction or side effect of COVID-19 vaccine: https://ncbi.nlm.nih.gov/33824804/
  3. the culprit: https://pubmed.ncbi.nlm.nih.gov/34702550/
  4. A case of acute encephalopathy and non-ST-segment elevation myocardial infarction aftervaccination with mRNA-1273: possible adverse effect: https:// ncbi.nlm.nih.gov/34703815/
  5. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34292611/.
  6. Chouchana, , Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. https:// www.ncbi.nlm.nih.gov/pubmed/34860360
  1. Three cases of acute venous thromboembolism in women after vaccination against COVID-19: https://sciencedirect.com/science/article/pii/S2213333X21003929
  2. Acute thrombosis of the coronary tree after vaccination against COVID-19: https://sciencedirect.com/science/article/abs/pii/S1936879821003988
  3. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination withCOV2.S (against covid-19), March 2 to April 21, 2020: https:// pubmed.ncbi.nlm.nih.gov/33929487/
  4. Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: https://thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/
  5. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study ofHemostasis and Thrombosis (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
  6. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: https://sciencedirect.com/science/article/abs/pii/S0735675721004381
  7. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: https://sciencedirect.com/science/ article/abs/pii/S0033062021000505
  8. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://sciencedirect.com/science/article/abs/pii/S0953620521001904


  1. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause ofsplanchnic vein thrombosis: https://sciencedirect.com/ science/article/pii/S1665268121000557
  2. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): https:// sciencedirect.com/science/article/pii/S1050173821000967
  3. Roots of autoimmunity of thrombotic events after COVID-19 vaccination: https://sciencedirect.com/science/article/abs/pii/S1568997221002160
  4. Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https://nejm.org/doi/full/10.1056/nejme2106315
  5. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://nejm.org/doi/full/10.1056/NEJMoa2104882? query=recirc_curatedRelated_article
  6. Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: https://nejm.org/doi/full/10.1056/NEJMoa2104840? query=recirc_curatedRelated_article
  7. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19):https://haematologica.org/article/view/haematol.2021.279075
  8. Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://sciencedirect.com/science/article/abs/pii/ S0896841121000895
  9. Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: https://sciencedirect.com/science/ article/abs/pii/S0049384821003315
  10. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https://sciencedirect.com/science/article/pii/S0953620521002363
  11. “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient withantiphospholipid syndrome”: https://sciencedirect.com/science/ article/pii/S2666572721000389
  12. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://sciencedirect.com/science/article/pii/S0196064421003425
  13. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: https://sciencedirect.com/ science/article/abs/pii/S0896841121000706
  14. Prothrombotic immune thrombocytopenia after COVID-19 vaccination: https://sciencedirect.com/science/article/pii/S0006497121009411
  15. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: https://sciencedirect.com/science/article/pii/S2589936821000256
  16. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https://sciencedirect.com/science/article/pii/S0049384821004369
  17. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: https://sciencedirect.com/science/article/pii/S0953620521002314


  1. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: https://pubmed.ncbi.nlm.nih.gov/33918932/
  2. Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: https://ncbi.nlm.nih.gov/34181446/
  3. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https://nature.com/ articles/s41591-021-01408-4
  4. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: https://nejm.org/doi/full/10.1056/NEJMc2106383
  5. Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: https://nature.com/articles/s41586-021-03744-4
  6. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. https://sciencedirect.com/science/article/abs/pii/S0735675721004381.
  7. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic andtherapeutic recommendations for a new syndrome: https:// ncbi.nlm.nih.gov/33987882/
  8. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34138513/
  9. Intracerebral haemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/ 34402235/
  10. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https:// ncbi.nlm.nih.gov/34446426/
  11. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: https:// ncbi.nlm.nih.gov/34365148/.
  12. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https:// ncbi.nlm.nih.gov/34256983/
  13. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration ofAstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34132839/
  14. 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 daysafter a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34117206/
  15. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
  16. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://pubmed.ncbi.nlm.nih.gov/34139631/.
  17. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https:// ncbi.nlm.nih.gov/33864750/


  1. celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: https:// ncbi.nlm.nih.gov/34261633/.
  2. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: https:// ncbi.nlm.nih.gov/34256983/
  3. Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: https://ncbi.nlm.nih.gov/34236343/
  4. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://pubmed.ncbi.nlm.nih.gov/34092488/
  5. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: https:// ncbi.nlm.nih.gov/34132839/.
  6. Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers: https:// ncbi.nlm.nih.gov/34083026/.
  7. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: https://pubmed.ncbi.nlm.nih.gov/34235757/.
  8. Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34473841/.
  9. Cutaneous thrombosis associated with cutaneous necrosis following Oxford- AstraZeneca COVID-19vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
  10. Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: https://ncbi.nlm.nih.gov/34181446/
  11. Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34033367/
  12. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: https:// ncbi.nlm.nih.gov/34375510/
  13. Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34107198/
  14. Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: https:// ncbi.nlm.nih.gov/34355379/.
  15. Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with theChAdO × 1 nCov-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34474550/
  16. Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis afterSARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/ 34462996/
  17. Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: https://sciencedirect.com/science/article/pii/ S2214250921002018


  1. Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: https://casereports.bmj.com/content/14/5/e242220.abstract.
  2. Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34155844/
  3. Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: https://ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.
  4. Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: https://annemergmed.com/article/S0196-0644(21)00122-0/fulltext.
  5. Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: https://ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.
  6. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: https://casereports.bmj.com/content/14/7/e242678.
  7. Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34312301/.
  8. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/ 34455073/
  9. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventionalheparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
  10. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
  11. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https:// ncbi.nlm.nih.gov/34129181/
  12. S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: https:// pubmed.ncbi.nlm.nih.gov/33929487/.
  13. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https:// ncbi.nlm.nih.gov/34341358/
  14. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https:// ncbi.nlm.nih.gov/34175640/
  15. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https:// ncbi.nlm.nih.gov/34159588/.
  16. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/ 34402666/
  17. Autoimmunity roots of thrombotic events after vaccination with COVID-19: https://ncbi.nlm.nih.gov/34508917/


  1. Cerebral venous sinus thrombosis after vaccination: the UK experience: https://ncbi.nlm.nih.gov/34370974/
  2. Cutaneous thrombosis associated with cutaneous necrosis following Oxford- AstraZeneca COVID-19vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
  3. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: https://pubmed.ncbi.nlm.nih.gov/34650896/
  4. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): https://pubmed.ncbi.nlm.nih.gov/ 34672380/.
  5. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: https://pubmed.ncbi.nlm.nih.gov/34556531/.
  6. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34535076/.
  7. Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: https://pubmed.ncbi.nlm.nih.gov/34379914/.
  8. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: https://pubmed.ncbi.nlm.nih.gov/34545400/
  9. Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/ 34035134/
  10. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: https://pubmed.ncbi.nlm.nih.gov/34782400/
  11. Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: https://pubmed.ncbi.nlm.nih.gov/34660652/.
  12. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1(AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: https://pubmed.ncbi.nlm.nih.gov/34644642/
  13. Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: https://pubmed.ncbi.nlm.nih.gov/34694650/
  14. Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34726934/
  15. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: https://pubmed.ncbi.nlm.nih.gov/34835237/
  16. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia afterChAdOx1 nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
  17. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34724036/.
  18. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34839563/
  19. Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: https://ncbi.nlm.nih.gov/34783932/.


  1. COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades ofgray in thrombus formation: https://pubmed.ncbi.nlm.nih.gov/ 34624910/
  2. Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis withthrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/ 34580132/
  3. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: https:// ncbi.nlm.nih.gov/34272095/
  4. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https://com/journals/jamaneurology/fullarticle/2784622
  5. Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781321/
  6. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: https://pubmed.ncbi.nlm.nih.gov/34062319/
  7. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: https:// ncbi.nlm.nih.gov/34706921/
  8. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review andpost hoc analysis: https://pubmed.ncbi.nlm.nih.gov/34698582/
  9. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus- vectored COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34541935/
  10. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
  11. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS- CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34609603/
  12. Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severeacute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: https://pubmed.ncbi.nlm.nih.gov/34664303/.
  13. Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34649281/
  14. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: https:// ncbi.nlm.nih.gov/34610990/.
  15. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https://ncbi.nlm.nih.gov/34479129/
  16. Major artery thrombosis and vaccination against ChAdOx1 nCov-19: https://ncbi.nlm.nih.gov/34839830/
  17. Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: https://pubmed.ncbi.nlm.nih.gov/34595694/


  1. Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: https:// ncbi.nlm.nih.gov/34788138
  2. Thrombosis in pre- and post-vaccination phase of COVID-19; https://ncbi.nlm.nih.gov/34650382/
  3. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: https:// ncbi.nlm.nih.gov/34833382/
  4. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): https:// ncbi.nlm.nih.gov/34670287/
  5. An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34790811/
  6. Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: https://pubmed.ncbi.nlm.nih.gov/34023956/.
  7. Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: https://pubmed.ncbi.nlm.nih.gov/34629931/
  8. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/ 34402666/
  9. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19vaccination in a Taiwanese man: a case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34630307/
  10. Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: https://ncbi.nlm.nih.gov/33983464/
  11. Autoimmune roots of thrombotic events after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34508917/.
  12. New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: https://jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.
  13. Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34796065/.
  14. A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: https:// ncbi.nlm.nih.gov/34843991/
  15. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): https://pubmed.ncbi.nlm.nih.gov/34595867/
  16. A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine(Pfizer-Biontech): https://pubmed.ncbi.nlm.nih.gov/34820240/
  17. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: https:// ncbi.nlm.nih.gov/33851389/


  1. Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34264151/
  2. Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: https://pubmed.ncbi.nlm.nih.gov/34755555/
  3. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirusdisease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/ 34840204/
  4. Deep venous thrombosis after vaccination with COV2.S in adult males: https://pubmed.ncbi.nlm.nih.gov/34659839/.
  5. Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; https://jnnp.bmj.com/content/early/2021/09/29/

jnnp-2021-327340.

  1. COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: https:// pubmed.ncbi.nlm.nih.gov/34632750/
  2. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: https://org/article/view/haematol.2021.279075
  3. COVID-19 vaccine-induced thrombosis: https://pubmed.ncbi.nlm.nih.gov/34802488/.
  4. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: https:// ncbi.nlm.nih.gov/34887867/.
  5. Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34863404/.
  6. Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34876440/
  7. Deep venous thrombosis more than two weeks after COVID-19 vaccination: https://ncbi.nlm.nih.gov/33928773/
  8. Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34587242/
  9. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): https:// ncbi.nlm.nih.gov/34097311/
  10. Thrombocytopenia and splanchnic thrombosis after vaccination with COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258
  11. Chang, C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro- Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. https://www.ncbi.nlm.nih.gov/pubmed/34833382
  12. Potential risk of thrombotic events after COVID-19 vaccination with Oxford- AstraZeneca inwomen receiving estrogen: https://pubmed.ncbi.nlm.nih.gov/ 34734086/


  1. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
  2. Predicted and observed incidence of thromboembolic events among Koreans vaccinated with theChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34254476/
  3. Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352418/
  4. Shazley, , & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination:A Case-Study. Cureus, 13(7), e16383. doi:10.7759/cureus.16383. https://www.ncbi.nlm.nih.gov/pubmed/34408937
  1. Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulationand death after ChAdOx1 nCoV-19 vaccination: https:// ncbi.nlm.nih.gov/34171649/
  2. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination withCOV2.S (against covid-19), March 2 to April 21, 2020: https:// pubmed.ncbi.nlm.nih.gov/33929487/
  3. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study ofHemostasis and Thrombosis (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
  4. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: https://sciencedirect.com/science/article/pii/S0022510X21003014
  5. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: https://sciencedirect.com/science/article/abs/pii/S0735675721004381
  6. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: https://sciencedirect.com/science/ article/abs/pii/S0033062021000505
  7. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://sciencedirect.com/science/article/abs/pii/S0953620521001904
  8. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause ofsplanchnic vein thrombosis: https://sciencedirect.com/ science/article/pii/S1665268121000557
  9. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): https:// sciencedirect.com/science/article/pii/S1050173821000967
  10. Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https://nejm.org/doi/full/10.1056/nejme2106315


  1. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://nejm.org/doi/full/10.1056/NEJMoa2104882? query=recirc_curatedRelated_article
  2. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19):https://haematologica.org/article/view/haematol.2021.279075
  3. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccinesreported to the Vaccine Adverse Event Reporting System (VAERS):https://sciencedirect.com/science/article/pii/S0264410X21005247
  4. Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: https://sciencedirect.com/science/ article/abs/pii/S0049384821003315
  5. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https://sciencedirect.com/science/article/pii/S0953620521002363
  6. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://sciencedirect.com/science/article/pii/S0196064421003425
  7. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: https://sciencedirect.com/ science/article/abs/pii/S0896841121000706
  8. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: https://sciencedirect.com/science/article/pii/S2589936821000256
  9. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://sciencedirect.com/science/article/abs/pii/S088915912100163X
  10. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): https://sciencedirect.com/science/article/abs/pii/ S0006497121013963.
  11. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: https://sciencedirect.com/science/article/pii/S0953620521002314
  12. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: https://pubmed.ncbi.nlm.nih.gov/33918932/
  13. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: https://ncbi.nlm.nih.gov/33606296/
  14. Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33854395/
  15. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: https://ncbi.nlm.nih.gov/pmc/articles/PMC7996471/
  16. Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: https://ncbi.nlm.nih.gov/34181446/
  17. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https://nature.com/ articles/s41591-021-01408-4


  1. Exacerbation of immune thrombocytopenia after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34075578/
  2. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: https://nejm.org/doi/full/10.1056/NEJMc2106383
  3. Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: https://nature.com/articles/s41586-021-03744-4
  4. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. https://sciencedirect.com/science/article/abs/pii/S0735675721004381.
  5. Immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine: https://sciencedirect.com/science/article/pii/ S2214250921002018.
  6. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic andtherapeutic recommendations for a new syndrome: https:// ncbi.nlm.nih.gov/33987882/
  7. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34138513/
  8. Intracerebral haemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/ 34402235/
  9. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https:// ncbi.nlm.nih.gov/34446426/
  10. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: https:// ncbi.nlm.nih.gov/34365148/.
  11. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https:// ncbi.nlm.nih.gov/34256983/
  12. Cerebral venous thrombosis and vaccine-induced a. Oxford- AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: https://pubmed.ncbi.nlm.nih.gov/34033927/
  13. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: https://ncbi.nlm.nih.gov/33476455/
  14. Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34377889/
  15. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
  16. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https:// ncbi.nlm.nih.gov/33864750/
  17. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https:// ncbi.nlm.nih.gov/34446426/


  1. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: https:// ncbi.nlm.nih.gov/34108714/
  2. Thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/ 34332437/.
  3. A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/ 34137813/
  4. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/ 34191218/
  5. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https:// ncbi.nlm.nih.gov/34175640/
  6. Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: https:// ncbi.nlm.nih.gov/34011137/.
  7. Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34071883/
  8. Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
  9. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with theBNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105247/.
  10. Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34405870/.
  11. Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34513446/
  12. Immune-mediated thrombocytopenia associated with COV2.S vaccine (Janssen; Johnson &Johnson): https://pubmed.ncbi.nlm.nih.gov/34469919/.
  13. Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: https://pubmed.ncbi.nlm.nih.gov/ 34516272/.
  14. COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases withunderlying hepatic problems: https://pubmed.ncbi.nlm.nih.gov/ 34509271/.
  15. Immune thrombocytopenia after vaccination during the COVID-19 pandemic: https://ncbi.nlm.nih.gov/34435486/
  16. Vaccine-induced thrombocytopenia with severe headache: https://ncbi.nlm.nih.gov/34525282/
  17. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: https:// ncbi.nlm.nih.gov/34393988/.


  1. Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: https:// ncbi.nlm.nih.gov/34407607/.
  2. Australian and New Zealand approach to the diagnosis and treatment of vaccine- induced immune thrombosis and immune thrombocytopenia: https:// ncbi.nlm.nih.gov/34490632/
  3. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33909350/
  4. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: https:// ncbi.nlm.nih.gov/34276917/
  5. Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https:// ncbi.nlm.nih.gov/34237213/.
  6. Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immunethrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/ 34268278/.
  7. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33990339/.
  8. A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenousthrombosis: https://pubmed.ncbi.nlm.nih.gov/34059191/
  9. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/
  10. Vaccine-induced thrombocytopenia with severe headache: https://ncbi.nlm.nih.gov/34525282/
  11. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:https://science.org/doi/10.1126/sciadv.abl8213
  12. Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcementCOV2.S: first documented case outside the U.S.: https:// pubmed.ncbi.nlm.nih.gov/34626338/
  13. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia aftercoronavirus-19 vaccination: https://europepmc.org/article/ PPR/PPR304469 435.
  14. VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34731555/
  15. Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entitywith heterogeneous clinical presentations: https:// ncbi.nlm.nih.gov/34159588/
  16. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine- induced immunethrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/ 34461442/
  17. Cerebral venous sinus thrombosis after vaccination: the UK experience: https://ncbi.nlm.nih.gov/34370974/


  1. Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34373413/
  2. Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT)after Covid vaccination with ChAdOx1 nCoV-19: https:// ncbi.nlm.nih.gov/34598301/
  3. Spontaneous HIT syndrome: knee replacement, infection and parallels with vaccine- induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/ 34144250/
  4. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. https:// ncbi.nlm.nih.gov/33877737/
  5. ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after107,720 doses of ChAdOx1 vaccination in Thailand: https:// ncbi.nlm.nih.gov/34483267/.
  6. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
  7. Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
  8. Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: https:// ncbi.nlm.nih.gov/34314875/.
  9. Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34384129/
  10. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin Glevels: https://pubmed.ncbi.nlm.nih.gov/ 34382387/
  11. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting thevenosplanchnic and pulmonary arterial circulation from a UK district general hospital: https://pubmed.ncbi.nlm.nih.gov/34535492/
  12. COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: https://ncbi.nlm.nih.gov/34527501/
  13. Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: https://pubmed.ncbi.nlm.nih.gov/34756770/
  14. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34751013/.
  15. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: https:// ncbi.nlm.nih.gov/33877737/
  16. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34646685/


  1. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccinesreported to the Vaccine Adverse Event Reporting System (VAERS):https://pubmed.ncbi.nlm.nih.gov/34006408/
  2. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34420249/
  3. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/
  4. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced byCOVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34546343/
  5. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34384129/.
  6. Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34653943/.
  7. Relapse of immune thrombocytopenia after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34591991/
  8. Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33962903/.
  9. Adenovirus interactions with platelets and coagulation and vaccine-induced immune thromboticthrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/
  10. Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: https://pubmed.ncbi.nlm.nih.gov/34835275/.
  11. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D- dimer in Thais after vaccination with ChAdOx1 nCoV-19: https:// ncbi.nlm.nih.gov/34568726/
  12. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thromboticthrombocytopenia or a coincidence due to underlying risk factors: https://ncbi.nlm.nih.gov/34820232/.
  13. Successful treatment of vaccine-induced immune thrombotic thrombocytopenia in a 26-year-old female patient: https://pubmed.ncbi.nlm.nih.gov/34614491/
  14. Case report: vaccine-induced immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: https:// ncbi.nlm.nih.gov/34790684/
  15. Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting asacute venous thromboembolism: https://pubmed.ncbi.nlm.nih.gov/ 34096082/
  16. Helms, M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/ JBM.S307047. https://www.ncbi.nlm.nih.gov/pubmed/33854395
  17. Hippisley-Cox, , Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . .

Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccinationand SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. https://www.ncbi.nlm.nih.gov/ pubmed/34446426


  1. Lee, J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M.

D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS- CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. https:// www.ncbi.nlm.nih.gov/pubmed/33606296

  1. Welsh, J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021).

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332.doi:10.1016/j.vaccine.2021.04.054. https:// www.ncbi.nlm.nih.gov/pubmed/34006408

  1. Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: https://pubmed.ncbi.nlm.nih.gov/34804803/.
  2. Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia- induced SARS-CoV-2vaccination: https://pubmed.ncbi.nlm.nih.gov/34549178/.
  1. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirusand after COVID-19: https://sciencedirect.com/ science/article/pii/S0735109721051949
  2. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventionalheparin-warfarin based anticoagulation:https://sciencedirect.com/science/article/pii/S1871402121002046
  3. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: https://sciencedirect.com/science/article/abs/pii/S1052305721003098
  4. Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: https://thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext
  5. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination withCOV2.S (against covid-19), March 2 to April 21, 2020: https:// pubmed.ncbi.nlm.nih.gov/33929487/
  6. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study ofHemostasis and Thrombosis (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
  7. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: https://sciencedirect.com/science/article/pii/S0022510X21003014
  8. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://sciencedirect.com/science/article/pii/S0196064421003425
  9. A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19vaccination: https://sciencedirect.com/science/article/ pii/S0735675721005714


  1. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://sciencedirect.com/science/article/abs/pii/S088915912100163X
  2. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management ofcerebral venous thrombosis related to COVID-19 vaccination: https://sciencedirect.com/science/article/pii/S0213485321000839
  3. COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data fromVigiBase: https://pubmed.ncbi.nlm.nih.gov/33863748/
  4. Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: https://onlinelibrary.wiley.com/doi/10.1002/ana.26172
  5. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: https://pubmed.ncbi.nlm.nih.gov/ 34133027/
  6. The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34001390/
  7. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia afterimmunization with COVID-19 vaccine in an elderly, non- comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. https://sciencedirect.com/science/article/pii/S1871402121002046.
  8. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: https:// ncbi.nlm.nih.gov/34365148/.
  9. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporallyassociated with administration of COVID-19 vaccine: https:// ncbi.nlm.nih.gov/33917902/
  10. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
  11. Cerebral venous thrombosis and vaccine-induced a. Oxford- AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: https://pubmed.ncbi.nlm.nih.gov/34033927/
  12. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/ 33914590/
  13. Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: https://ncbi.nlm.nih.gov/34420802/
  14. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https:// ncbi.nlm.nih.gov/34293217/
  15. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
  16. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https://ncbi.nlm.nih.gov/34288044/


  1. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https:// ncbi.nlm.nih.gov/34341358/
  2. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33845870/.
  3. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https:// ncbi.nlm.nih.gov/34478433/
  4. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventionalheparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
  5. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/
  6. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/33687691/
  7. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: https:// ncbi.nlm.nih.gov/34393988/.
  8. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https:// ncbi.nlm.nih.gov/34129181/.
  9. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
  10. Cerebral venous thrombosis following COVID-19 vaccination: https://ncbi.nlm.nih.gov/34045111/.
  11. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): https:// ncbi.nlm.nih.gov/34092166/
  12. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https://ncbi.nlm.nih.gov/34288044/.
  13. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
  14. Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33878469/.
  15. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https:// ncbi.nlm.nih.gov/33857630/.
  16. Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: https://ncbi.nlm.nih.gov/34090750/.
  17. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34333995/
  18. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34111775/.


  1. Cerebral venous thrombosis after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34045111/
  2. Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: https://ncbi.nlm.nih.gov/33983464/
  3. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirusand after COVID-19: https://pubmed.ncbi.nlm.nih.gov/ 34116145/
  4. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: https:// ncbi.nlm.nih.gov/34286453/.
  5. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https:// ncbi.nlm.nih.gov/34478433/
  6. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: https://pubmed.ncbi.nlm.nih.gov/34244448/
  7. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https:// ncbi.nlm.nih.gov/34226070/
  8. Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19:https://pubmed.ncbi.nlm.nih.gov/33845870/.
  9. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/.
  10. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/ 34092166/
  11. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https:// ncbi.nlm.nih.gov/34293217/
  12. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZenecavaccination: https://pubmed.ncbi.nlm.nih.gov/34274191/
  13. Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/ 34373991/
  14. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34261296/
  15. Cerebral venous thrombosis developing after COVID-19: VITT, VATT, TTS and more: https://pubmed.ncbi.nlm.nih.gov/34695859/
  16. Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: https://pubmed.ncbi.nlm.nih.gov/34453762/.
  17. Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford- AstraZeneca COVID-19: amissed opportunity for rapid return on experience: https://sciencedirect.com/science/article/pii/S235255682100093X


  1. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: https:// ncbi.nlm.nih.gov/34880826/
  1. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https://sciencedirect.com/science/article/pii/S0272638621007423
  2. propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34451967/
  3. IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: https://ncbi.nlm.nih.gov/34509658/
  4. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34196469/
  5. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS- CoV-2 vaccination:victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/.
  6. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS- CoV-2 vaccination:victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/
  7. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): https://pubmed.ncbi.nlm.nih.gov/34546608/
  8. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34853744/.
  9. Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: https:// ncbi.nlm.nih.gov/34755433/
  10. Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: https://pubmed.ncbi.nlm.nih.gov/34726187/.
  11. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34859017/
  12. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34783899/
  13. COVID-19 vaccine-induced urticarial vasculitis: https://pubmed.ncbi.nlm.nih.gov/ 34369046/.
  14. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https://ncbi.nlm.nih.gov/34280507/.
  15. New-onset leukocytoclastic vasculitis after COVID-19 vaccine: https://ncbi.nlm.nih.gov/34241833/
  16. Cutaneous small vessel vasculitis after COVID-19 vaccine: https://ncbi.nlm.nih.gov/34529877/.


  1. Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: https://ncbi.nlm.nih.gov/33928638/
  2. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: https://ncbi.nlm.nih.gov/34836739/
  3. Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; https://pubmed.ncbi.nlm.nih.gov/34495381/.
  4. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine:https://pubmed.ncbi.nlm.nih.gov/34327795
  5. Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: https://ncbi.nlm.nih.gov/34660867/.
  6. Reactivation of IgA vasculitis after vaccination with COVID-19: https://ncbi.nlm.nih.gov/34848431/
  7. Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34310759/.
  8. Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: https://pubmed.ncbi.nlm.nih.gov/34720009/
  9. Cutaneous vasculitis following COVID-19 vaccination: https://ncbi.nlm.nih.gov/34611627/.
  10. Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: https://ncbi.nlm.nih.gov/34705320/.
  11. IgA vasculitis following COVID-19 vaccination in an adult: https://ncbi.nlm.nih.gov/34779011/
  12. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34451967/
  13. Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: https:// ncbi.nlm.nih.gov/33928459/
  14. Reactivation of IgA vasculitis after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34250509/
  15. First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: https://pubmed.ncbi.nlm.nih.gov/34530771/.
  16. Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: https://pubmed.ncbi.nlm.nih.gov/34245294/.
  17. Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34599716/.
  18. Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance ofeosinophils: https://pubmed.ncbi.nlm.nih.gov/34115904/.
  19. Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: https://ncbi.nlm.nih.gov/34237323/.
  20. A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34849386/
  21. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS- CoV-2: https://pubmed.ncbi.nlm.nih.gov/34310763/


  1. Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34557622/.
  2. Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: https://ncbi.nlm.nih.gov/34713472/803
  3. Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS- CoV-2: https://pubmed.ncbi.nlm.nih.gov/34819272/
  4. Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34337124/
  5. Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: https://pubmed.ncbi.nlm.nih.gov/34535924/
  6. Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: https://ncbi.nlm.nih.gov/34251683/.
  1. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: https://sciencedirect.com/science/article/pii/S2666354621000065
  2. Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association:https://sciencedirect.com/science/article/pii/S0303846721004169
  3. Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of theliterature: https://sciencedirect.com/science/article/pii/ S0165572821002186
  4. Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causalassociation: https://sciencedirect.com/science/article/ pii/S2214250921000998.
  5. Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a casereport: https://sciencedirect.com/science/article/pii/ S0736467921006442
  6. Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://sciencedirect.com/science/article/pii/S0035378721005853.
  7. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: https://sciencedirect.com/science/article/pii/S2049080121005343
  8. Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: https://pubmed.ncbi.nlm.nih.gov/34477091/
  9. A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: https://pubmed.ncbi.nlm.nih.gov/34449715/


  1. Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34416410/.
  2. Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: https://pubmed.ncbi.nlm.nih.gov/34447646/
  3. Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34548920/
  4. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: https://pubmed.ncbi.nlm.nih.gov/34560365/
  5. COVID-19, Guillain-Barré and vaccineA dangerous mix: https://ncbi.nlm.nih.gov/34108736/.
  6. Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: https://pubmed.ncbi.nlm.nih.gov/ 34796417/.
  7. Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: https://springer.com/article/10.1007%2Fs10072-021-05523-5.
  8. COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: https://onlinelibrary.wiley.com/doi/10.1002/ana.26258.
  9. Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barresyndrome, February-July 2021: https://jamanetwork.com/ journals/jama/fullarticle/2785009
  10. A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: https://ncbi.nlm.nih.gov/34567447/
  11. Guillain-Barré syndrome associated with COVID-19 vaccination: https://ncbi.nlm.nih.gov/34648420/.
  12. Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708
  13. Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: https://pedneur.com/article/S0887-8994(21)00221-6/fulltext.
  14. Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: https://ncbi.nlm.nih.gov/34114256/.
  15. Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: https://ncbi.nlm.nih.gov/34767184/.
  16. Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: https://ncbi.nlm.nih.gov/34644738/.
  17. Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: https://pubmed.ncbi.nlm.nih.gov/34649856/
  18. A rare case of Guillain-Barré syndrome after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34671572/
  19. Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33758714/
  20. COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: https://pubmed.ncbi.nlm.nih.gov/34484780/


  1. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; https://pubmed.ncbi.nlm.nih.gov/34779385/.
  2. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://pubmed.ncbi.nlm.nih.gov/34217513/.
  3. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): https:// ncbi.nlm.nih.gov/34871447/
  4. A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: https://ncbi.nlm.nih.gov/34370408/.
  5. A rare variant of Guillain-Barré syndrome after vaccination with COV2.S:https://pubmed.ncbi.nlm.nih.gov/34703690/.
  6. Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: https://pubmed.ncbi.nlm.nih.gov/ 34810163/
  7. Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: https://onlinelibrary.wiley.com/doi/10.1002/ana.26218

 

  1. Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: https://ncbi.nlm.nih.gov/34114269/
  2. Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: https://pubmed.ncbi.nlm.nih.gov/34722067/
  3. Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not acausal association: https://pubmed.ncbi.nlm.nih.gov/33968610/
  4. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: https://pubmed.ncbi.nlm.nih.gov/34525410/
  5. Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019coronavirus disease vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34808658/
  6. Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/ 34848426/
  7. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261746/
  1. Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: https:// ncbi.nlm.nih.gov/34667486/
  2. COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: https://pubmed.ncbi.nlm.nih.gov/33591026/
  3. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: https://pubmed.ncbi.nlm.nih.gov/33625300/


  1. Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: https://pubmed.ncbi.nlm.nih.gov/33774684/
  2. Lymphadenopathy after COVID-19 vaccination: review of imaging findings: https://ncbi.nlm.nih.gov/33985872/
  3. Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: https:// ncbi.nlm.nih.gov/34115709/.
  4. COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysisof 163 cases: https://pubmed.ncbi.nlm.nih.gov/34257025/.
  5. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: https:// ncbi.nlm.nih.gov/34280870/
  6. COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: https://pubmed.ncbi.nlm.nih.gov/34432391/
  7. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: https:// ncbi.nlm.nih.gov/34731748/
  8. Adverse events of COVID injection that may occur in children.Acute-onset supraclavicularlymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
  9. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow- up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
  10. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/ 33661328/
  11. A case of cervical lymphadenopathy following COVID-19 vaccination: https://ncbi.nlm.nih.gov/34141500/
  12. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
  13. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-weekwait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/ 33685772/
  14. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
  15. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https:// ncbi.nlm.nih.gov/34526175/
  16. Lymphadenopathy associated with the COVID-19 vaccine: https://ncbi.nlm.nih.gov/33786231/
  17. Evolution of lymphadenopathy on PET/MRI
  18. Massive cervical lymphadenopathy following vaccination with COVID-19: https://ncbi.nlm.nih.gov/34601889/


  1. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/ 33706861/
  2. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow- up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
  3. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/ 33661328/
  4. A case of cervical lymphadenopathy following COVID-19 vaccination: https://ncbi.nlm.nih.gov/34141500/
  5. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
  6. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-weekwait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/ 33685772/
  7. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
  8. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https:// ncbi.nlm.nih.gov/34526175/
  9. Lymphadenopathy associated with the COVID-19 vaccine: https://ncbi.nlm.nih.gov/33786231/
  10. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: https://ncbi.nlm.nih.gov/33625301/.
  11. Massive cervical lymphadenopathy following vaccination with COVID-19: https://ncbi.nlm.nih.gov/34601889/
  12. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previousbreast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
  13. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow- up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/.
  14. Evolution of Lymphadenopathy at Pet/MRI after COVID-19 vaccination: https://ncbi.nlm.nih.gov/33625301/
  1. COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the WorldAllergy Organization:. https://sciencedirect.com/ science/article/pii/S1939455121000119.
  2. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer- BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33475702/


  1. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer- BioNTech COVID-19 vaccine – United States, December 14-23, 2020: https:// ncbi.nlm.nih.gov/33444297/
  2. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – UnitedStates, December 21, 2020-January 10, 2021: https:// ncbi.nlm.nih.gov/33507892/
  3. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: https://pubmed.ncbi.nlm.nih.gov/34414880/
  4. Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the S.-Dec 14, 2020-Jan 18, 2021: https://pubmed.ncbi.nlm.nih.gov/33576785/
  5. Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: https://pubmed.ncbi.nlm.nih.gov/34269740/
  6. Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34215453/
  7. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: https://pubmed.ncbi.nlm.nih.gov/33932618/
  8. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: https://ncbi.nlm.nih.gov/33571463/
  9. Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: https:// ncbi.nlm.nih.gov/34347278/
  10. COVID-19 vaccines increase the risk of anaphylaxis: https://ncbi.nlm.nih.gov/33685103/
  11. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccineCOVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
  12. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33825239/
  13. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: https://pubmed.ncbi.nlm.nih.gov/34128049/
  14. .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34318537/
  15. Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.
  16. Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: https://ncbi.nlm.nih.gov/33851711/
  17. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: https://pubmed.ncbi.nlm.nih.gov/34675550/.
  18. Anaphylaxis after Modern COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34734159/
  19. Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: https://pubmed.ncbi.nlm.nih.gov/34020815/


  1. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer- BioNTech COVID-19vaccine – United States, December 14 to 23, 2020: https:// ncbi.nlm.nih.gov/33641264/
  2. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine –United States, December 21, 2020 to January 10, 2021: https:// ncbi.nlm.nih.gov/33641268/
  3. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: https://pubmed.ncbi.nlm.nih.gov/33834172/
  4. Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: https://pubmed.ncbi.nlm.nih.gov/ 34579211/
  5. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positivepolysorbate 80 skin test result: https://pubmed.ncbi.nlm.nih.gov/ 34343674/
  6. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
  7. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
  8. Iguchi, , Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). CumulativeAdverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9.https://www.ncbi.nlm.nih.gov/ pubmed/34347278
  9. Team, C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi: 10.15585/mmwr.mm7002e1. https://www.ncbi.nlm.nih.gov/pubmed/33444297
  1. Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: https://sciencedirect.com/science/article/pii/S002234762100665X
  2. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: https://sciencedirect.com/science/article/pii/S0022347621007368
  3. Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: https://sciencedirect.com/science/article/pii/ S0022347621007496
  4. Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis https:// oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059
  5. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. https://sciencedirect.com/science/article/abs/pii/S188558572100133X


  1. Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidentalintravenous injection of a vaccine induce myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34453510/
  2. COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: https://medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.
  3. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: https://t.co/j0IEM8cMXI
  4. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
  5. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: https://pubmed.ncbi.nlm.nih.gov/34636504/
  6. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34228985/
  7. Acute myopericarditis after COVID-19 vaccine in adolescents: https://ncbi.nlm.nih.gov/34589238/
  8. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. https://www.ncbi.nlm.nih.gov/pubmed/ 34889875
  9. Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, , Mallenahalli Chikkabyrappa, S., & Portman, M. A.(2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine inAdolescents. J Pediatr, 238, 317-320. doi: 10.1016/j.jpeds.2021.06.083. https://www.ncbi.nlm.nih.gov/pubmed/34228985
  10. Kohli, , Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. https:// www.ncbi.nlm.nih.gov/pubmed/34952008
  11. Long, S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds. 2021.07.057. https://www.ncbi.nlm.nih.gov/pubmed/34332972
  12. McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male followingCOVID-19 vaccination: A case Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322. https://www.ncbi.nlm.nih.gov/pubmed/

34133825

  1. Umei, C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open.doi:10.1016/j.cjco.2021.12.002. https://www.ncbi.nlm.nih.gov/ pubmed/34904134
  2. Das, B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021).Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi: 10.1016/j.jpeds.2021.07.044. https://www.ncbi.nlm.nih.gov/pubmed/34339728
  3. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, , Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccinationand Myo-Pericarditis in Patients Receiving Immune Checkpoint


Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/ vaccines9010019. https://www.ncbi.nlm.nih.gov/pubmed/33406694

  1. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
  1. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: https://sciencedirect.com/science/article/pii/ S2213219821007972
  2. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer- BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33475702/
  3. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: https://pubmed.ncbi.nlm.nih.gov/33320974/
  4. Pfizer Vaccine Raises Allergy Concerns: https://pubmed.ncbi.nlm.nih.gov/33384356/
  5. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer- BioNTech COVID-19 vaccine – United States, December 14-23, 2020: https:// ncbi.nlm.nih.gov/33444297/
  6. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – UnitedStates, December 21, 2020-January 10, 2021: https:// ncbi.nlm.nih.gov/33507892/
  7. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association ofAllergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): https://pubmed.ncbi.nlm.nih.gov/33643776/
  8. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: https://ncbi.nlm.nih.gov/33571463/
  9. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethyleneglycol and IgG-mediated complement activation: https:// ncbi.nlm.nih.gov/33657648/
  10. Acute allergic reactions to COVID-19 mRNA vaccines: https://ncbi.nlm.nih.gov/33683290/
  11. Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipientand management of future exposure to SARS-CoV2: https:// ncbi.nlm.nih.gov/33919151/
  12. Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: https://pubmed.ncbi.nlm.nih.gov/34474708/
  13. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): https://tandfonline.com/doi/abs/ 10.1080/17843286.2021.1909447


  1. Allergic reactions after COVID-19 vaccination: putting the risk in perspective: https://ncbi.nlm.nih.gov/34463751/
  2. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical An ETFAD position statement with external experts: https://pubmed.ncbi.nlm.nih.gov/33752263/
  3. Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34698847/
  4. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J AllergyClin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. https://www.ncbi.nlm.nih.gov/pubmed/34153517
  5. Klimek, , Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . .

. Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper fromGerman and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. https:// www.ncbi.nlm.nih.gov/pubmed/33898162

  1. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA:Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi: 10.1007/s40629-020-00160-4. https://ncbi.nlm.nih.gov/pubmed/33643776
  2. Warren, C. M., Snow, T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021).Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524. doi:10.1001/jamanetworkopen.2021.25524. https://www.ncbi.nlm.nih.gov/pubmed/34533570
  1. Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: https://sciencedirect.com/science/article/pii/S1473309921002735
  2. Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: https://sciencedirect.com/science/article/pii/ S266635462100020X
  3. Bell’s palsy after COVID-19 vaccination: case report: https://sciencedirect.com/science/article/pii/S217358082100122X.
  4. The association between COVID-19 vaccination and Bell’s palsy: https://ncbi.nlm.nih.gov/34411533/


  1. Bell’s palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33611630/
  2. Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: https://ncbi.nlm.nih.gov/34336436/
  3. Bell’s palsy after COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34014316/
  4. Bell’s palsy after COVID-19 vaccination: case report: https://ncbi.nlm.nih.gov/34330676/
  5. Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: https://ncbi.nlm.nih.gov/33975372/.
  6. Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: https://ncbi.nlm.nih.gov/34322761/.
  7. Bell’s palsy after a single dose of vaccine SARS-CoV-2: case report: https://pubmed.ncbi.nlm.nih.gov/34032902/.
  8. Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: https://thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext.
  9. Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence:https://pubmed.ncbi.nlm.nih.gov/34522557/
  10. Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report:https://pubmed.ncbi.nlm.nih.gov/34763263/.
  11. Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: https://pubmed.ncbi.nlm.nih.gov/34621891/
  12. Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: https:// ncbi.nlm.nih.gov/34411532/
  13. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/34272622/
  14. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: https://pubmed.ncbi.nlm.nih.gov/33858693/

 

 

 
  1. COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: https://sciencedirect.com/science/article/pii/S1930043321002612
  2. Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/ 34735411/
  3. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: https://pubmed.ncbi.nlm.nih.gov/34836672/.


  1. Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: https://pubmed.ncbi.nlm.nih.gov/34906409/
  2. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/ 33624520/
  3. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https://pubmed.ncbi.nlm.nih.gov/34298342/
  4. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previousbreast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
  5. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19:https://pubmed.ncbi.nlm.nih.gov/34292295/.
  6. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRIallowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/ 34325221/
  7. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
  8. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
  9. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/ 33624520/
  10. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https://pubmed.ncbi.nlm.nih.gov/34298342/
  11. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19:https://pubmed.ncbi.nlm.nih.gov/34292295/.
  12. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRIallowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/ 34325221/
  13. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
  14. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
  15. Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/ 33625299/.
  1. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for careproviders: https://sciencedirect.com/science/article/pii/ S0828282X21006243


  1. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: https://sciencedirect.com/science/article/pii/S1443950621011562
  2. Myocarditis and pericarditis after COVID-19 vaccination: https://jamanetwork.com/journals/jama/fullarticle/2782900
  3. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine:https://sciencedirect.com/science/article/pii/S1885585721002218
  4. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNAvaccine in Korean children: a multicenter study https:// bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc e/en/ covidwho-1360706.
  5. Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34340927/
  6. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19mRNA: https://cps.ca/en/documents/position/ clinical-guidance-for-youth-with-myocarditis-and-pericarditis
  7. Myocarditis / pericarditis associated with COVID-19 vaccine: https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html
  8. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: https://pubmed.ncbi.nlm.nih.gov/34236331/
  9. Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: https://ncbi.nlm.nih.gov/34364831/
  10. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: https://pubmed.ncbi.nlm.nih.gov/34447639/
  11. A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports fromEurope and the United States: https://pubmed.ncbi.nlm.nih.gov/ 34635376/
  12. Acute pericarditis and cardiac tamponade after vaccination with Covid-19: https://ncbi.nlm.nih.gov/34749492/
  13. Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: https://ncbi.nlm.nih.gov/34149145/
  14. Case report: symptomatic pericarditis post COVID-19 vaccination: https://ncbi.nlm.nih.gov/34693198/.

 
  1. Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: https://sciencedirect.com/science/article/pii/S0165572821002137


  1. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19- associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222):https://pubmed.ncbi.nlm.nih.gov/33981305/
  2. Transverse myelitis induced by SARS-CoV-2 vaccination: https://ncbi.nlm.nih.gov/34458035/
  3. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19- associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine:https://pubmed.ncbi.nlm.nih.gov/33981305/.
  4. Acute transverse myelitis after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34684047/.
  5. Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34641797/.
  6. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34482455/.
  7. Acute transverse myelitis following inactivated COVID-19 vaccine: https://ncbi.nlm.nih.gov/34370410/
  8. Acute transverse myelitis after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34579245/.
  9. A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34182207/
  10. Post COVID-19 transverse myelitis; a case report with review of the literature: https://ncbi.nlm.nih.gov/34457267/.
  11. Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34131771/
  12. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.
  13. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.
  14. Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34849183/

 

 

 

 
  1. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https://oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543


  1. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https://ncbi.nlm.nih.gov/34319393/
  2. Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: https://pubmed.ncbi.nlm.nih.gov/34447639/
  3. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: https://biomedcentral.com/articles/10.1186/s12872-021-02183
  4. Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: https://ncbi.nlm.nih.gov/34515024/
  5. Perimyocarditis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/ 34866957/
  6. Tinoco, , Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). PerimyocarditisFollowing COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177/11795468211056634. https://

www.ncbi.nlm.nih.gov/pubmed/34866957

  1. Jhaveri, , Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green,

M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNAVaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061.https://www.ncbi.nlm.nih.gov/pubmed/34270752

  1. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Cureus, 13(7), e16590. doi:10.7759/cureus.16590. https://www.ncbi.nlm.nih.gov/pubmed/ 34447639
  2. Hasnie, A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S.
  3. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in ahealthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3.https://www.ncbi.nlm.nih.gov/pubmed/

34348657
  1. Intracerebral haemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination:the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/ 34402235/
  2. Intracerebral haemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34477089/
  3. Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
  4. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https:// ncbi.nlm.nih.gov/34108714/


  1. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34273119/
  2. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: https://ncbi.nlm.nih.gov/34273119/
  3. Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 Brain MRI revealed an intracerebral haemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. https://www.sciencedirect.com/science/article/pii/ S2589238X21000292#f0005
  4. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: https://pubmed.ncbi.nlm.nih.gov/34579636/
  1. Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality orvictim?: https://pubmed.ncbi.nlm.nih.gov/33862041/
  2. Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: https://ncbi.nlm.nih.gov/34332438/
  3. Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: https:// ncbi.nlm.nih.gov/34293683/.
  4. Autoimmune hepatitis after COVID vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34225251/
  5. Hepatitis C virus reactivation after COVID-19 vaccination: a case report: https://ncbi.nlm.nih.gov/34512037/
  6. Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford- AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34171435/
  7. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: https://ncbi.nlm.nih.gov/34332438/.
  8. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: https://sciencedirect.com/science/article/pii/S0168827821020936
  1. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: https://sciencedirect.com/science/article/pii/ S1201971221007049
  2. COVID-19 vaccination association and facial nerve palsy: A case-control study: https://pubmed.ncbi.nlm.nih.gov/34165512/
  3. Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34281950/.


  1. Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): https://ncbi.nlm.nih.gov/33734623/
  2. Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self- report database: https://pubmed.ncbi.nlm.nih.gov/34492394/
  3. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19vaccination: https://pubmed.ncbi.nlm.nih.gov/34272622/
  1. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: https://sciencedirect.com/science/article/pii/ S0899707121003557.
  2. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: https://pubmed.ncbi.nlm.nih.gov/34507266/
  3. Spectrum of neurological complications after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34719776/.
  4. n-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/ 34688190/
  5. Neurological side effects of SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/ 34750810/
  6. Neurological complications after the first dose of COVID-19 vaccines and SARS- CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34697502/
  1. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA- based SARS-CoV-2 vaccine: https://ncbi.nlm.nih.gov/labs/pmc/articles/ PMC8553377/
  2. Retinal hemorrhage after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/ 34884407/.
  3. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS- CoV-2 mRNA-based SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34729467/
  4. Acral hemorrhage after administration of the second dose of SARS-CoV-2 A post-vaccination reaction: https://pubmed.ncbi.nlm.nih.gov/34092400/742.
  5. Fatal cerebral hemorrhage after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/ 33928772/


  1. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
  1. Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/ 33946748/
  2. Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34549821/
  3. Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine:https://onlinelibrary.wiley.com/doi/10.1111/trf.16672
  4. https://ncbi.nlm.nih.gov/pubmed/34127481
  5. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: https://ncbi.nlm.nih.gov/34846583/
  6. Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNAvaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/ 33946748/
  1. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: https://sciencedirect.com/science/article/pii/S1443950621011562
  2. Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: https://sciencedirect.com/science/article/pii/S1443950621011331
  3. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: https://ncbi.nlm.nih.gov/34625447/
  4. Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: https://pubmed.ncbi.nlm.nih.gov/34731486/.
  5. Takotsubo syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/ 34539938/.


  1. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https://journals.lww.com/pidj/Abstract/9000/ Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx
  2. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, , Lowenthal, A., Ayalon, I., . . . Bilavsky, E.(2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363. doi:10.1097/INF.0000000000003235. https://www.ncbi.nlm.nih.gov/pubmed/ 34077949
  3. Fazlollahi, , Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318.https://www.ncbi.nlm.nih.gov/pubmed/34921468
  4. Ho, S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K.

(2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. https://www.ncbi.nlm.nih.gov/ pubmed/34808708

  1. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiacinvolvement in a patient with previous SARS-COV-2 infection: https://sciencedirect.com/science/article/pii/S2352906721000622

 

 

  1. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findingsand Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24). doi:10.3390/

jcm10245876. https://www.ncbi.nlm.nih.gov/pubmed/34945172

 

  1. Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34591186/
  2. A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiologyof COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: https://pubmed.ncbi.nlm.nih.gov/34769454/
  3. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/

 

  1. Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34591186/


 

  1. Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: https://ncbi.nlm.nih.gov/34435250/
  2. COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: https://pubmed.ncbi.nlm.nih.gov/34186348/
  3. COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: https://sciencedirect.com/science/article/pii/S1871402121001880
  4. Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: https://ncbi.nlm.nih.gov/34435250/.
  5. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmuneglomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34659268/
  1. Thrombotic thrombocytopenic purpura after vaccination with COV2-S: https://pubmed.ncbi.nlm.nih.gov/33980419/
  2. Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34264514/.
  3. Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: https://ncbi.nlm.nih.gov/34754937/
  4. Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer- BioNTech BNT16B2b2: https://pubmed.ncbi.nlm.nih.gov/34077572/
  1. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccineshttps://cureus.com/articles/61030-myocarditis-and-other- cardiovascular-complications-of-the-mrna-based-covid-19-vaccines
  2. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://jcmr-biomedcentral.com/articles/10.1186/s12968-021-00795-4


  1. Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: https://xiahepublishing.com/m/2472-0712/ERHM-2021-00033
  2. Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
  1. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: https://sciencedirect.com/science/article/pii/S2049080121007536
  2. Post-vaccinal encephalitis after ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/ 34324214/
  3. Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34325334/
  4. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: https://pubmed.ncbi.nlm.nih.gov/ 34512961/
  1. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34242687/.
  2. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352309/
  3. AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
  4. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
  1. Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report:https://pubmed.ncbi.nlm.nih.gov/34447349/
  2. Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: https://pubmed.ncbi.nlm.nih.gov/ 34015240


  1. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNAvaccines in a patient with multiple sclerosis treated with teriflunomide: https://pubmed.ncbi.nlm.nih.gov/34696248/

 

 

 
  1. A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34518812/
  2. Henoch-Schönlein purpura occurring after vaccination with COVID-19: https://ncbi.nlm.nih.gov/34247902/.
  3. Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34696186/.
  1. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis ofEuropean data: https://sciencedirect.com/science/ article/pii/S0896841121000937
  2. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
  3. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
  1. Cutaneous adverse effects of available COVID-19 vaccines: https://ncbi.nlm.nih.gov/34518015/
  2. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34363637/
  3. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19:a prospective cohort study in health care workers: https://pubmed.ncbi.nlm.nih.gov/34661934/


 

  1. A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma LindaUniversity: https://pubmed.ncbi.nlm.nih.gov/34423106/
  2. Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/
  3. Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross- sectional study of 405 cases: https://pubmed.ncbi.nlm.nih.gov/34254291/

 

 

  1. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: https://pubmed.ncbi.nlm.nih.gov/34639132/
  2. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report:https://pubmed.ncbi.nlm.nih.gov/34615534/
  3. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpectedprothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.
  4. https://www.ncbi.nlm.nih.gov/pubmed/34366403

 

 

  1. Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34852213/

 

  1. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome?Vaccines (Basel), 9(11). doi:10.3390/ vaccines9111353. https://ncbi.nlm.nih.gov/pubmed/34835284


  1. Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa. 16141.

 
  1. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34462013/.
  2. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/
  1. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34459725/
  2. Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
  1. Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- oradenoviral vector-based SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34291477/
  2. Ntouros, P. , Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis,P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765.doi:10.1016/j.clim.2021.108765. https://www.ncbi.nlm.nih.gov/pubmed/34089859


  1. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34513435/
  2. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: https://ejhp.bmj.com/content/early/2021/05/23/ ejhpharm-2021-002794
  1. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: https://ncbi.nlm.nih.gov/pmc/articles/PMC7996471/
  2. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination:https://pubmed.ncbi.nlm.nih.gov/34236717/
  1. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
  2. A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: https://pubmed.ncbi.nlm.nih.gov/34452028/
  1. Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford- AstraZeneca / Covishield): report of two cases: https://pubmed.ncbi.nlm.nih.gov/ 34350668/
  2. Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: https://pubmed.ncbi.nlm.nih.gov/34427024/


 

 

  1. Miller Fisher syndrome after Pfizer COVID-19 vaccine: https://ncbi.nlm.nih.gov/34817727/.
  2. Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: https://ncbi.nlm.nih.gov/34789193/.

 

  1. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: https://ncbi.nlm.nih.gov/34250318/.
  2. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/

 

 

  1. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/

 

  1. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS- CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33932458/

 

 
  1. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: https://sciencedirect.com/science/article/pii/ S1876034121001878.


  1. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34482558/
  1. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34406660/.
  2. Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): https://pubmed.ncbi.nlm.nih.gov/34862234/
  1. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: https:// ncbi.nlm.nih.gov/34804412/
  2. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: https:// ncbi.nlm.nih.gov/34807248/

 

 

  1. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/

 

  1. Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndromecoronavirus 2 mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/ 34660149/


  1. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34631069/
  2. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/ 34510694/

 

  1. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
  1. Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: https://docs.google.com/document/d/ 1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ
  1. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105244/
  1. New-onset refractory status epilepticus after chadox1 ncov-19 vaccination: https://sciencedirect.com/science/article/pii/s0165572821001569


  1. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:.https://sciencedirect.com/science/article/pii/S2451993621001456.
  1. Late cutaneous reactions after administration of COVID-19 mRNA vaccines: https://sciencedirect.com/science/article/pii/S2213219821007996
  1. COVID-19 RNA-based vaccines and the risk of prion disease: https://com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion-dis ease-1503.pdf
  1. This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on thesafety of covid-19 vaccines: https://nejm.org/doi/ full/10.1056/NEJMoa2104983.
  1. Process-related impurities in the ChAdOx1 nCov-19 vaccine: https://researchsquare.com/article/rs-477964/v1
  1. COVID-19 mRNA vaccine causing CNS inflammation: a case series: https://springer.com/article/10.1007/s00415-021-10780-7


  1. A systematic review of cases of CNS demyelination following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34839149/
  1. Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: https://pubmed.ncbi.nlm.nih.gov/33527524/
  1. Fatal brain haemorrhage after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/ 33928772/
  1. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34851795/.
  1. Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: https://pubmed.ncbi.nlm.nih.gov/ 34452064/.


  1. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/ 34369471/

 

 

 

 

 

 
  1. Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on:“Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al.Articular Spine 2021; 88: 10519: https://pubmed.ncbi.nlm.nih.gov/34139321/.
  1. Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: https://ncbi.nlm.nih.gov/34287612/

 

 

  1. Lipschütz ulcers after AstraZeneca COVID-19 vaccination: https://ncbi.nlm.nih.gov/34366434/.


  1. Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: https://pubmed.ncbi.nlm.nih.gov/34330677/

 

  1. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: https://pubmed.ncbi.nlm.nih.gov/34463066/

 

  1. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: https://pubmed.ncbi.nlm.nih.gov/34043800/.
  1. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vectorvaccine: https://pubmed.ncbi.nlm.nih.gov/34483273/.
  1. Reactive arthritis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/ 34033732/.


  1. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: https://ncbi.nlm.nih.gov/34462647/
  1. Tolosa-Hunt syndrome occurring after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34513398/
  1. Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: https://ncbi.nlm.nih.gov/34436620/
  1. Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34429981/
  1. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34510014/.


  1. Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34236711/
  1. Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2vaccination: https://ashpublications.org/bloodadvances/ article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic

 
  1. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria:https://ashpublications.org/blood/article/137/26/3670/475905/ COVID-19-vaccines-induce-severe-hemolysis-in

 
  1. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: https://pubmed.ncbi.nlm.nih.gov/34313952/
  1. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute CoronarySyndrome as measured by PULS cardiac testing: a caution:https://ahajournals.org/doi/10.1161/circ.144.suppl_1.10712

 


  1. ANCA glomerulonephritis following Modern COVID-19 vaccination: https://ncbi.nlm.nih.gov/34081948/
  1. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/

 

  1. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: https://sciencedirect.com/science/article/pii/S1201971221007797

 

 

 

  1. Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: https://nature.com/articles/

s41421-021-00329-3

 

 

  1. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/33771584/


  1. Inflammatory myositis after vaccination with ChAdOx1: https://ncbi.nlm.nih.gov/34585145/
  1. An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: https://pubmed.ncbi.nlm.nih.gov/34797392/
  1. Case report: Pityriasis rosea-like rash after vaccination with COVID-19: https://ncbi.nlm.nih.gov/34557507/
  1. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: https://pubmed.ncbi.nlm.nih.gov/34812326/.
  1. Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34590397/


  1. Sudden sensorineural hearing loss after COVID-19 vaccination: https://ncbi.nlm.nih.gov/34670143/.
  1. Prevalence of serious adverse events among health care professionals after receiving the first dose ofChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: https://pubmed.ncbi.nlm.nih.gov/34819146/.
  1. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): https://pubmed.ncbi.nlm.nih.gov/34751429/.
  1. Ocular adverse events following COVID-19 vaccination: https://ncbi.nlm.nih.gov/34559576/
  1. Depression after ChAdOx1-S / nCoV-19 vaccination: https://ncbi.nlm.nih.gov/34608345/.


  1. Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: https://ncbi.nlm.nih.gov/34781027/
  1. Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: https://ncbi.nlm.nih.gov/34581453/
  1. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: https://pubmed.ncbi.nlm.nih.gov/34741583/
  1. Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndromeinduced by adjuvants: https://pubmed.ncbi.nlm.nih.gov/ 33858208/
  1. Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1nCoV-19, and COV2.S vaccines: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34710832/


  1. Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: https://pubmed.ncbi.nlm.nih.gov/34868465/
  1. Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: https://ncbi.nlm.nih.gov/34753210/.
  1. COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: https://pubmed.ncbi.nlm.nih.gov/34786893/

 

  1. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34842783/
  1. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: https://pubmed.ncbi.nlm.nih.gov/ 34579248/
  1. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: https://pubmed.ncbi.nlm.nih.gov/34571653/.


 

  1. Idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33624509/.
  1. Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): https://pubmed.ncbi.nlm.nih.gov/ 34612003/
  1. Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccinemanufactured by Moderna: https://pubmed.ncbi.nlm.nih.gov/ 34866106/

 

  1. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionalityanalysis in VigiBase: https://pubmed.ncbi.nlm.nih.gov/34579259/
  1. Brain death in a vaccinated patient with COVID-19 infection: https://ncbi.nlm.nih.gov/34656887/


  1. Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: https://ncbi.nlm.nih.gov/34148772/
  1. Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination:case report: https://frontiersin.org/articles/10.3389/fmed. 2021.798095/

 

  1. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https://ncbi.nlm.nih.gov/34187985/
  1. Colaneri, , De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. https:// www.ncbi.nlm.nih.gov/pubmed/34547487

 

 

  1. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis doi:10.1002/ art.41977. https://www.ncbi.nlm.nih.gov/pubmed/34492161


  1. Hause, M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay,
  2. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14,2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31),

1053-1058. doi:10.15585/mmwr.mm7031e1. https://www.ncbi.nlm.nih.gov/pubmed/

34351881

 

 

  1. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T.
  2. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2. https://www.ncbi.nlm.nih.gov/pubmed/33956784

 

 

  1. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: https://pubmed.ncbi.nlm.nih.gov/34219532/
  2. Deb, , Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events ReportingSystem Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. https://

www.ncbi.nlm.nih.gov/pubmed/34219532
  1. Furer, , Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam,
  2. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/ annrheumdis-2021-220647. https://www.ncbi.nlm.nih.gov/pubmed/34127481


  1. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series:https://pubmed.ncbi.nlm.nih.gov/34668274/.


  1. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V- REPP: a registry-based study: https://www.sciencedirect.com/science/article/pii/ S0190962221024427


  1. Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: https:// pubmed.ncbi.nlm.nih.gov/34487581/

 

Può interessarti anche: Austria: cosa vuole sapere la Corte Costituzionale dal ministero della salute. Le domande scomode

Seguici su Facebook https://www.facebook.com/presskit.it

Seguici su Telegram https://t.me/presskit

 

 

 

 

 

 

 

Altri articoli interessanti

Dott. Philip Buchholz

“Il vaccino Pfizer è contaminato dal DNA plasmatico”, la testimonianza del dott. Philip Buchholz alla commissione per gli affari medici del Senato della Carolina del Sud

miocardite

Miocarditi aumentate dopo l’inizio delle vaccinazioni Covid, l’analisi di Hart

Lettera all'editore pubblicata oggi su Medical Research Archives, due scienziati della Children's Health Defense hanno chiesto un'indagine su come i funzionari della sanità pubblica degli Stati Uniti abbiano soppresso le prove che collegano miocardite e vaccini COVID-19.

Hanno soppresso le prove che collegano la miocardite ai vaccini. La denuncia in una lettera al Medical Research Archives

FDA

L’FDA riconosce che i vaccini Covid per i minori aumentano il rischio di miocardite

Proteina spike da vaccino, possibili danni

Turbo cancro: effetti collaterali sul sangue dei vaccini a mRNA. La denuncia del dott. Peter F. Mayer

cuore

Pfizer file: quasi 400 eventi cardiaci avversi maggiori nei 21 giorni dalla somministrazione del vaccino

Social Media Auto Publish Powered By : XYZScripts.com